

AMENDMENTS

Kindly make the following changes:

In the Specification:

On page 1, line 7, after "1994," please add --abandoned,--.

On page 1, line 10, please add --, abandoned-- after "1994".

On page 1, line 21, please replace "Moossor" with --Moossa--.

On page 4, lines 13-15, please replace the first sentence with --A "therapy sensitizing gene activity" is meant to be a gene product whose loss of normal function or regulation renders cancer cells more resistant to therapy.--.

In the Claims:

Please cancel claims 21 and 22 without prejudice to future prosecution thereof.

Please amend claims 1-3, 6, 9, 10, 12-15, 17-20 and 23, and add new claims 24-28.

1. (Amended) [Method] A method of increasing the therapeutic effect of a cancer therapy, comprising the steps of:

delivering to a tumor cell which has lost by mutation or deletion its wild type p53 gene, a gene conferring wild type p53 therapy sensitizing gene activity,

effecting the expression of said wild type p53 therapy sensitizing gene activity in said tumor cell, and

[delivering wild-type therapy-sensitizing gene activity to a tumor cell
characterized by loss of said wild-type therapy-sensitizing gene activity, and]
subjecting said tumor cell to said cancer therapy.

2. (Amended) A method of increasing the therapeutic effect of a cancer therapy,
comprising the steps of:

delivering to a tumor cell which has lost by mutation or deletion its wild type
p53 gene, a protein having wild type p53 therapy sensitizing gene activity, and
subjecting said tumor cell to said cancer therapy.

[The method of claim 1, wherein said delivering comprises introducing a
portion of a therapy-sensitizing protein with said therapy-sensitization gene activity into the
tumor cell.]

3. (Amended) The method of claim 1, wherein said gene conferring wild type
p53 therapy sensitizing gene activity is wild type p53 gene.

[The method of claim 1, wherein said delivering comprises introducing a
portion of a therapy-sensitizing gene encoding said therapy-sensitizing gene activity or a
portion of a cDNA encoding said therapy-sensitizing gene activity into the tumor cell.]

6. (Amended) The method of claim 1, wherein said cancer therapy is immunotherapy [biological therapy].

9. (Amended) The method of claim 1 wherein said tumor cell is selected from the group consisting of [carcinoma cell, sarcoma cell, central nervous system tumor cell, melanoma tumor cell,] leukemia cell, lymphoma tumor cell, [hematopoietic tumor cell,] ovarian carcinoma cell, osteogenic sarcoma cell, lung carcinoma cell, colorectal carcinoma cell, hepatocellular carcinoma cell, glioblastoma cell, prostate cancer cell, breast cancer cell, bladder cancer cell, kidney cancer cell, pancreatic cancer cell, gastric cancer cell, esophageal cancer cell, anal cancer cell, biliary cancer cell, and urogenital cancer cell[, and head and neck cancer cell].

10. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is in a vector.

12. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is coupled to a virus capsid or particle.

13. (Amended) The method of claim 12, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is coupled to said capsid or particle through a polylysine bridge.

14. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is encapsulated in a liposome.

15. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is conjugated to a ligand.

17. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is introduced to said tumor cell by direct injection.

18. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is introduced to said tumor cell by intra-arterial infusion.

19. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is introduced to said tumor cell by intracavitary infusion.

20. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is introduced to said tumor cell by intravenous infusion.

23. (Amended) The method of claim [3] 1, wherein said [portion of a therapy-sensitizing gene or said portion of a cDNA] gene conferring wild type p53 therapy sensitizing gene activity is introduced to said tumor cell in aerosolized preparation.

24. (New) The method of claim 1 wherein said tumor cell is selected from the group consisting of carcinoma cell, sarcoma cell, and melanoma cell.

25. (New) The method of claim 1 wherein said tumor cell is selected from the group consisting of central nervous system tumor cell, hematopoietic tumor cell, and head and neck cancer cell.